Core Viewpoint - HaiXi Pharmaceutical has successfully completed its IPO subscription, raising significant interest with an oversubscription of 3113 times the initial public offering amount, indicating strong market demand for its shares [1] Group 1: IPO Details - HaiXi Pharmaceutical's IPO took place from October 9 to 14, with a total of HKD 3.094 billion in margin loans borrowed by brokers [1] - The company plans to issue 11.5 million H-shares, with a public offering price range between HKD 69.88 and HKD 86.4, aiming to raise up to HKD 990 million [1] - The expected listing date is October 17, with Huatai International and China Merchants Jinling International serving as joint sponsors [1] Group 2: Business Overview - HaiXi Pharmaceutical is a commercial-stage pharmaceutical company engaged in research, development, production, and sales, with a pipeline of innovative drugs under development [1] - The company has a portfolio of generic drugs targeting various diseases, including gastrointestinal, cardiovascular, endocrine, neurological, and inflammatory diseases, with 15 generic drugs approved by the National Medical Products Administration [1] - Four of these generic drugs are included in the national volume-based procurement (VBP) program [1] Group 3: Innovative Drug Pipeline - The company's innovative drug pipeline includes a novel oncology drug and an oral medication for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [2] - The fastest progressing drug in the pipeline is C019199, targeting osteosarcoma, which is set to enter Phase III trials in the second half of this year [2] Group 4: Financial Performance - The company's projected revenues for 2022, 2023, 2024, and the five months ending May 31, 2025, are RMB 212.5 million, RMB 316.6 million, RMB 466.7 million, and RMB 249.2 million, respectively [2] - Corresponding gross profits for the same periods are RMB 172.1 million, RMB 263.6 million, RMB 387.2 million, and RMB 209.3 million [2] Group 5: Use of Proceeds - Approximately 52% of the net proceeds from the fundraising will be allocated to ongoing research and development to advance the drug pipeline [3] - 23% will be used to enhance R&D capabilities and seek collaboration opportunities, while 8% will focus on improving commercialization capabilities and expanding market influence [3] - Additional allocations include 7% for optimizing R&D and production systems, and 10% for working capital and other general corporate purposes [3]
新股消息 | 海西新药(02637)招股结束 孖展认购资金达3094亿港元 超购3113倍